Ranolazine
Product Images NDC 45963-418

7 FDA label images from Actavis Pharma, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Ranolazine (NDC 45963-418). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

FDA Label Image

1 (Image 2)

FDA Label Image

1 (Image 3)

1 (Image 3)
Chemical structure of Ranolazine showing the molecular arrangement of atoms and bonds in its compound.*
FDA Label Image

1 (Image 4)

FDA Label Image

1 (Image 5)

FDA Label Image

1 (Image 6)

1 (Image 6)
Label for Ranolazine Extended-Release Tablets 500 mg by Actavis Pharma, Inc. The bottle contains 60 swallow tablets to be taken whole, not crushed or chewed. The label includes storage instructions, formulation details, dispensing guidance, and manufacturer information (Teva Pharmaceuticals USA, Inc.).*
FDA Label Image

1 (Image 7)

1 (Image 7)
Ranolazine Extended-Release Tablets 1,000 mg label from Actavis Pharma, Inc. The label indicates 60 tablets per container, with instructions to swallow whole without crushing or chewing. It includes storage conditions, dosage reference to literature, and a barcode with lot and expiration information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.